INSIGHTS ON CLINICAL TRIAL DESIGN

• Developing And Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays

  Receptor occupancy (RO) assays assess drug-target engagement and support PK/PD modeling. Accurate RO requires customized assays using stabilized blood to monitor CD6 modulation in autoimmune therapy.

• Medical Insight's Role In Early-Phase Clinical Development

  Medical insight reduces risk, strengthens protocols, and accelerates timelines — enhancing safety, feasibility, and collaboration for successful trials and reliable outcomes.

• Making Early Decisions In Psychiatric Drug Development

  Quantitative PD measures provide objective evidence of target engagement, support dose selection, strengthen early go/no-go decisions, and help reduce development risk in psychiatric

• The Next Frontier In Early Phase Oncology Trials

  This session explores the pivotal role of First-in-Human and early phase oncology trials in drug development, emphasizing the importance of comprehensive planning for successful execution.

• Mastering Scope 3 Emissions In Clinical Trials

  10/23/2024

  Explore innovative strategies for reducing Scope 3 emissions in clinical trials. Discover sustainable solutions that uphold quality and outcomes, crucial for achieving net-zero goals in healthcare research.

• Challenges And New Approaches To Developing Clinical Evidence For Medical Devices

  9/12/2024

  Learn about the challenges and new approaches to developing clinical evidence for medical devices, including decentralized trials, adaptive studies, in silico trials, and real-world evidence.

• The Future Of Patient Experience: Lessons From GLP-1 Studies

  7/29/2026

  Improve adherence, retention, and data quality in GLP-1 and cardiometabolic trials through connected digital tools, real-time symptom tracking, caregiver support, and AI-assisted review.

• Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems

  10/7/2025

  Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.

• No More Back And Forth: Building eCOAs Right The First Time

  5/27/2025

  Clinical trial system builds have long been plagued by inefficiencies, miscommunications, and long timelines. Learn about a platform helping sponsors and CRO's overcome these challenges.